A year later, FDA approved COBAS EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)for the detection of EGFR mutations in liquid biopsy, when tissue biopsy is not available, to identify metastatic NSCLC patients eligible for anti-EGFR treatment. Here, EGFR is linked to non-small cell lung carcinoma.